Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07527910 | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | PHASE2 | NOT YET_RECRUITING | 204 | — | — | Apr 20, 2026 | Nov 27, 2029 | Apr 14, 2026 | - | — |
Part A
| Arm | Type | Description |
|---|---|---|
| Part A: A1 | EXPERIMENTAL | - |
| Part A: A2 | EXPERIMENTAL | - |
| Part B: B1 | EXPERIMENTAL | - |
| Part B: B2 | EXPERIMENTAL | - |
| Part B: B3 | EXPERIMENTAL | - |
| Part B: B4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALN-PNP | DRUG | Administered per the protocol |
| Tirzepatide | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol Placebo matching ALN-PNP |
Key Inclusion Criteria: Part A and Part B: 1. Homozygous for the PNPLA3 p.I148M genotype 2. Liver fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) ≥15% at visit 3 3. Has a Body Mass Index (BMI) ≥30 to \<45 kg/m\^2 at visit 2 Part A: To be eligible for randomization on stud...